Author

Florian Lüke

University Hospital RegensburgORCID 0000-0001-5252-287XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Rainer ClausiD· 2 shared Albrecht StenzingeriD· 1 shared Amirhossein SakhtemaniD· 1 shared Andrea StutziD· 1 shared Andreas SchneeweißiD· 1 shared Andreas Unterberg· 1 shared Annika SchneideriD· 1 shared Barbara HutteriD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Rainer ClausORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJul 9, 2026

Prospective pan-cancer phosphoproteomics at clinical scale extends therapeutic options in precision oncology

Annika Schneider, Julia Wortmann, Cecilia Bang Jensen…·Bernhard Küster

This study uses pan-cancer phosphoproteomics to identify therapeutic targets and improve precision oncology by analyzing 1,998 tumor samples and developing new scores for kinase activity and immune response.

DOI 10.64898/2026.07.08.737171

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintFeb 9, 2026

Ex vivo drug testing in metastatic biopsies reveals patient-specific vulnerabilities to cancer targeting and immune activating drugs

Lukas Wöhrl, Durdam Das, Kathrin Weidele…·Christian Werno

This study introduces PEDRA, an ex vivo drug response assay that identifies patient-specific treatment options in metastatic biopsies, outperforming prior therapies and informing immune responses.

DOI 10.64898/2026.02.06.704037

humanexperimental assay

𝕏 PostBluesky